Disability Related Feature Stories and Live Breaking News

Disability Nexus

Subscribe to Disability Nexus : eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Disability Nexus : homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn

Top Stories

SALT LAKE CITY, Jan. 15, 2013 /PRNewswire/ -- Lineagen, Inc. today announced publication of the results of a 9,000-person genetic study that demonstrates an approximately 100% increase in the detection rate of genetic markers now validated as being associated with autism spectrum disorders (ASDs).  The study, one of the largest genetic validation studies in autism, was designed to confirm novel copy number genetic variants and novel next-generation sequence variants associated with ASDs.  Researchers affiliated with The Children's Hospital of Philadelphia (CHOP), the University of Utah (Utah), Golden Helix, Inc, and Lineagen have confirmed in family and broad population studies a two-fold increase in the number of cases of ASD that can be ascribed to these newly identified genetic variants, specifically gene deletions or duplications (termed copy number variants, or... (more)

Inclusion Has Come A Long Way..

Inclusion has come a long way. I attended an elementary school in BC in the early 1970’s as a ward of the Province. At that time, inclusion meant the public school system, but a separate classroom and curriculum. All the children with a recognizable disability were in the same classroom. At recess we segregated ourselves. It was a BIG deal when early in grade five, I was finally admitted to the “regular” classroom. My peers had been prepared for my arrival by a well-meaning system and teacher that failed to take into account my feelings as the “object” of discussion. I wasn’t pre... (more)

An Introduction to My Health 2.0 Blog

As I am new to "Ulitzer" I thought perhaps before I began with writing & posting articles, I would take this opportunity to better introduce myself.  On November 6, 2007  I suffered a workplace injury that resulted in permanent disability and chronic pain 24/7. I have also been forced to fight every step of the way with WSIB, aka the Workplace Safety and Insurance Board-(the worker's comp. board) in Ontario, Canada. I was recently asked to describe what I thought of them in one sentence and this was my reply: "Straight from the depths of hell with virulent cruelty, WSIB's primary ... (more)

2013 Reading in Review

I was planning on taking a very, very long road to assembling the graphic below, but I am glad I did some research first. It saved me from learning how to create WordPress plugins, or toying around with the Goodreads API, which I will most likely still do at some point. It was a great year for my reading. 89 books, graphics novels, Audible, etc. I plan to bump it up even more in 2014. Below the image, I have pulled in the more in depth reviews of the books in descending order based on my star ratings. .gr_custom_container_1388710762 { /* customize your Goodreads widget contain... (more)

'Sharing Miracles' Television Program to Feature Four-Time World Series Champ Darryl Strawberry

WASHINGTON, July 29 /PRNewswire-USNewswire/ -- Four-Time World Series champion and legendary Major League Baseball slugger Darryl Strawberry will be featured on this month's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every Sunday morning on more than 300 television stations nationwide. Darryl Strawberry burst onto the baseball scene at a young age, joining the New York Mets at only 21 years old and earning National League Rookie-of-the-Year honors. Dur... (more)

Merck Serono Receives Refuse to File Letter From FDA on Cladribine Tablets New Drug Application

GENEVA, November 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that its US affiliate received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS). "The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point ... (more)